The/DT
Effect/JJ
of/IN
Increasing/VBG
Control-to-case/NN
Ratio/NN
on/IN
Statistical/JJ
Power/NN
in/IN
a/DT
Simulated/JJ
Case-control/NN
SNP/NN
Association/NN
Study/NN
./.
====================
Generally/RB
,/,
larger/JJR
sample/NN
size/NN
leads/VBZ
to/TO
a/DT
greater/JJR
statistical/JJ
power/JJR
to/TO
detect/VB
a/DT
significant/JJ
difference/NN
./.
====================
We/PRP
may/MD
increase/VB
the/DT
sample/NN
size/NN
for/IN
both/DT
case/NN
and/CC
control/NN
in/IN
order/NN
to/TO
obtain/VB
greater/JJR
power/JJR
./.
====================
However/RB
,/,
it/PRP
is/VBZ
often/RB
the/DT
case/NN
that/DT
increasing/VBG
sample/NN
size/NN
for/IN
case/NN
is/VBZ
not/RB
feasible/JJ
for/IN
a/DT
variety/NN
of/IN
reasons/NNS
./.
====================
In/IN
order/NN
to/TO
look/VB
at/IN
change/NN
in/IN
power/JJR
as/IN
the/DT
ratio/NN
of/IN
control/JJ
to/TO
case/NN
varies/VBZ
(/(
1:1/CD
to/TO
4:1/CD
)/)
,/,
we/PRP
conduct/VBP
association/NN
tests/NNS
with/IN
simulated/JJ
data/NNS
generated/VBD
by/IN
PLINK/NN
./.
====================
The/DT
simulated/JJ
data/NNS
consist/VBP
of/IN
50/CD
disease/NN
SNPs/NNS
and/CC
300/CD
non-disease/NN
SNPs/NNS
and/CC
we/PRP
compute/VBP
powers/NNS
for/IN
disease/NN
SNPs/NNS
./.
====================
Genetic/JJ
Power/NN
Calculator/NN
was/VBD
used/VBN
for/IN
computing/VBG
powers/NNS
with/IN
varying/VBG
the/DT
ratio/NN
of/IN
control/JJ
to/TO
case/NN
(/(
1:1/CD
,/,
2:1/CD
,/,
3:1/CD
,/,
4:1/CD
)/)
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
show/VBP
that/IN
gains/NNS
in/IN
statistical/JJ
power/JJR
resulting/VBG
from/IN
increasing/VBG
the/DT
ratio/NN
of/IN
control/JJ
to/TO
case/NN
are/VBP
substantial/JJ
for/IN
the/DT
simulated/JJ
data/NNS
./.
====================
Similar/JJ
results/NNS
might/MD
be/VB
expected/VBN
for/IN
real/JJ
data/NNS
./.
====================
The/DT
power/JJR
of/IN
a/DT
study/NN
is/VBZ
the/DT
probability/NN
that/DT
the/DT
test/NN
will/MD
reject/VB
a/DT
null/JJ
hypothesis/NN
that/IN
is/VBZ
in/IN
fact/NN
false/IN
./.
====================
As/IN
power/JJR
increases/VBZ
,/,
the/DT
probability/NN
of/IN
a/DT
Type/NN
II/CD
error/NN
(/(
false/VBP
negative/JJ
rate/NN
=β/JJ
)/)
decreases/VBZ
(/(
Fig/NN
./.
====================
1/CD
)/)
./.
====================
Therefore/RB
power/JJR
is/VBZ
1β/JJ
./.
====================
Decreasing/VBG
β/NN
error/NN
is/VBZ
equivalent/JJ
to/TO
increasing/VBG
statistical/JJ
power/NN
(/(
Fig/NN
./.
====================
2/CD
)/)
./.
====================
Power/JJR
depends/VBZ
on/IN
several/JJ
factors/NNS
such/JJ
as/IN
prevalence/NN
,/,
magnitude/NN
of/IN
effect/NN
,/,
sample/NN
size/NN
,/,
and/CC
required/VBD
level/NN
of/IN
statistical/JJ
significance/NN
α/IN
./.
====================
When/WRB
computing/VBG
statistical/JJ
power/JJR
in/IN
matched/VBN
case-control/JJ
studies/NNS
(/(
Dupont/JJ
,/,
1988/CD
)/)
,/,
we/PRP
need/VBD
to/TO
know/VB
a/DT
pre-specified/JJ
type/NN
I/CD
error/NN
rate/NN
,/,
the/DT
ratio/NN
of/IN
control/JJ
to/TO
case/NN
,/,
estimated/VBN
number/NN
of/IN
cases/NNS
,/,
the/DT
prevalence/NN
of/IN
exposure/NN
in/IN
the/DT
control/JJ
group/NN
,/,
minimum/JJ
odds/NNS
ratio/NN
declared/VBD
to/TO
be/VB
significant/JJ
and/CC
correlation/NN
coefficient/JJ
for/IN
exposure/NN
between/IN
cases/NNS
and/CC
their/PRP$
matched/VBN
controls/NNS
./.
====================
Hennessy/RB
S/NN
described/VBN
the/DT
effect/NN
of/IN
increasing/VBG
the/DT
ratio/NN
of/IN
control/JJ
to/TO
case/NN
for/IN
different/JJ
values/NNS
of/IN
correlation/NN
coefficients/NNS
and/CC
prevalence/NN
among/IN
controls/NNS
in/IN
matched/VBN
casecontrol/NN
studies/NNS
(/(
Hennessy/RB
S/NN
et/FW
al./FW
,/,
1999/CD
)/)
./.
====================
For/IN
a/DT
detailed/JJ
review/NN
of/IN
power/JJR
and/CC
sample/NN
size/NN
computation/NN
in/IN
either/CC
genetic/JJ
studies/NNS
or/CC
genetic/JJ
epidemiology/NN
,/,
please/NN
refer/VBP
to/TO
Shork/NN
et/FW
al/JJ
./.
====================
(/(
2002/CD
)/)
,/,
Ambrosius/NN
et/FW
al/JJ
./.
====================
(/(
2004/CD
)/)
,/,
De/NNP
La/NN
Vega/NNP
et/FW
al/JJ
./.
====================
(/(
2005/CD
)/)
,/,
and/CC
Burton/NN
et/FW
al/JJ
./.
====================
(/(
2009/CD
)/)
./.
====================
In/IN
our/PRP$
study/NN
,/,
we/PRP
may/MD
focus/VB
on/IN
how/WRB
sample/JJ
size/NN
affects/VBZ
statistical/JJ
power/JJR
,/,
given/VBN
a/DT
set/NN
of/IN
population/NN
parameters/NNS
./.
====================
Generally/RB
,/,
increase/VBP
in/IN
sample/NN
size/NN
for/IN
both/DT
case/NN
and/CC
control/NN
leads/VBZ
to/TO
increase/VB
in/IN
statistical/JJ
power/JJR
./.
====================
There/EX
are/VBP
some/DT
situations/NNS
,/,
however/RB
,/,
where/WRB
increasing/VBG
sample/NN
size/NN
for/IN
case/NN
is/VBZ
not/RB
available/JJ
./.
====================
For/IN
example/NN
,/,
in/IN
rare/JJ
diseases/NNS
,/,
the/DT
cost/JJ
of/IN
including/VBG
additional/JJ
controls/NNS
is/VBZ
low/JJ
whereas/IN
that/DT
of/IN
including/VBG
cases/NNS
is/VBZ
high/JJ
./.
====================
In/IN
such/JJ
instances/NNS
,/,
we/PRP
increase/VBP
sample/NN
size/NN
for/IN
control/JJ
only/RB
and/CC
then/RB
see/VB
if/IN
the/DT
effect/NN
on/IN
statistical/JJ
power/JJR
is/VBZ
the/DT
same/JJ
as/IN
that/DT
obtained/VBN
when/WRB
the/DT
sample/JJ
size/NN
for/IN
both/DT
case/NN
and/CC
control/NN
increases/VBZ
./.
====================
Specifically/RB
,/,
we/PRP
examine/VBP
if/IN
increase/VBP
in/IN
the/DT
ratio/NN
of/IN
control/NN
to/TO
case/NN
has/VBZ
an/DT
effect/NN
on/IN
increasing/VBG
power/JJR
./.
====================
We/PRP
simulate/VBP
SNP/NN
data/NNS
as/IN
below/IN
and/CC
assess/VB
the/DT
effect/NN
of/IN
the/DT
ratio/NN
of/IN
control/JJ
to/TO
case/NN
on/IN
statistical/JJ
power/JJR
./.
====================
PLINK/NN
(/(
Purcell/NN
et/FW
al./FW
,/,
2007/CD
)/)
was/VBD
used/VBN
for/IN
generating/VBG
simulated/JJ
data/NNS
with/IN
50/CD
disease/NN
SNPs/NNS
and/CC
300/CD
nondisease/JJ
SNPs/NNS
(/(
Table/JJ
1/CD
)/)
./.
====================
In/IN
this/DT
data/NNS
,/,
we/PRP
fixed/VBD
the/DT
sample/JJ
size/NN
for/IN
case/NN
as/IN
50/CD
but/CC
the/DT
sample/JJ
size/NN
for/IN
control/JJ
size/NN
varies/VBZ
from/IN
50/CD
,/,
100/CD
,/,
150/CD
to/TO
200/CD
in/IN
order/NN
to/TO
investigate/VB
the/DT
effect/NN
of/IN
the/DT
ratio/NN
of/IN
control/JJ
to/TO
case/NN
on/IN
power/JJR
./.
====================
We/PRP
set/VBP
prevalence/NN
as/IN
0.5000/CD
,/,
0.3333/CD
,/,
0.2500/CD
,/,
and/CC
0.2000/CD
for/IN
four/CD
models/NNS
,/,
respectively/RB
./.
====================
First/RB
,/,
assuming/VBG
allele/NN
model/NN
,/,
we/PRP
computed/VBD
the/DT
number/NN
of/IN
significant/JJ
SNPs/NNS
for/IN
disease/NN
SNPs/NNS
,/,
non-disease/JJ
SNPs/NNS
,/,
and/CC
overall/JJ
SNPs/NNS
as/IN
the/DT
ratio/NN
of/IN
control/JJ
to/TO
case/NN
changes/NNS
./.
====================
We/PRP
also/RB
computed/VBD
the/DT
estimated/VBN
average/JJ
power/JJR
which/WDT
is/VBZ
equal/JJ
to/TO
E/NN
(/(
S/NN
)/)
/m/NN
(/(
eq1/NN
)/)
,/,
where/WRB
S/NN
is/VBZ
the/DT
number/NN
of/IN
SNPs/NNS
declared/VBD
to/TO
be/VB
significant/JJ
among/IN
disease/NN
SNPs/NNS
and/CC
m/NN
is/VBZ
the/DT
number/NN
of/IN
disease/NN
SNPs/NNS
./.
====================
Second/RB
,/,
we/PRP
examined/VBD
the/DT
power/JJ
for/IN
each/DT
disease/NN
SNP/NN
using/VBG
Genetic/JJ
Power/NN
Calculator/NN
(/(
Purcell/NN
S/NN
et/FW
al./FW
,/,
2003/CD
)/)
in/IN
order/NN
to/TO
see/VB
how/WRB
change/NN
in/IN
the/DT
ratio/NN
of/IN
control/JJ
to/TO
case/NN
affects/VBZ
the/DT
power/JJ
for/IN
the/DT
genetic/JJ
models/NNS
(/(
allele/NN
,/,
genotype/NN
,/,
dominant/JJ
,/,
and/CC
recessive/JJ
)/)
./.
====================
Table/JJ
2/CD
shows/VBZ
that/IN
the/DT
number/NN
of/IN
significant/JJ
SNPs/NNS
increases/VBZ
as/IN
the/DT
ratio/NN
of/IN
control/JJ
to/TO
case/NN
for/IN
allele/NN
model/NN
rises/NNS
from/IN
1:1/CD
to/TO
3:1/CD
./.
====================
The/DT
increase/NN
in/IN
the/DT
ratio/NN
of/IN
control/JJ
to/TO
case/NN
for/IN
disease/NN
SNPs/NNS
leads/VBZ
to/TO
increase/VB
in/IN
number/NN
of/IN
significant/JJ
SNPs/NNS
,/,
while/IN
the/DT
increase/NN
in/IN
the/DT
ratio/NN
of/IN
control/JJ
to/TO
case/NN
for/IN
nondisease/JJ
SNPs/NNS
leads/VBZ
to/TO
decrease/VB
in/IN
the/DT
number/NN
./.
====================
Therefore/RB
,/,
the/DT
number/NN
of/IN
significant/JJ
SNPs/NNS
decreases/VBZ
when/WRB
the/DT
ratio/NN
of/IN
control/JJ
to/TO
case/NN
increases/VBZ
from/IN
3:1/CD
to/TO
4:1/CD
./.
====================
We/PRP
might/MD
expect/VB
that/DT
the/DT
gain/NN
in/IN
average/JJ
power/JJR
shown/VBN
in/IN
eq1/NN
increases/VBZ
as/IN
the/DT
ratio/NN
of/IN
control/JJ
to/TO
case/NN
increases/VBZ
,/,
since/IN
the/DT
effect/NN
of/IN
the/DT
ratio/NN
of/IN
control/JJ
to/TO
case/NN
for/IN
disease/NN
SNPS/NN
on/IN
the/DT
number/NN
of/IN
significant/JJ
SNPs/NNS
is/VBZ
substantial/JJ
./.
====================
Assuming/VBG
allele/NN
model/NN
,/,
the/DT
average/NN
power/JJR
shown/VBN
in/IN
eq1/NN
increases/VBZ
for/IN
disease/NN
SNPs/NNS
as/IN
the/DT
ratio/NN
of/IN
control/JJ
to/TO
case/NN
increases/VBZ
(/(
Fig/NN
./.
====================
3/CD
)/)
./.
====================
In/IN
other/JJ
words/NNS
,/,
the/DT
power/NN
curve/NN
tends/NNS
to/TO
increase/VB
gradually/RB
./.
====================
On/IN
the/DT
other/JJ
hand/NN
,/,
in/IN
regard/NN
to/TO
computing/VBG
statistical/JJ
power/JJR
for/IN
each/DT
disease/NN
SNP/NN
,/,
for/IN
example/NN
,/,
the/DT
disease/NN
SNP/NN
3/CD
(/(
Fig/NN
./.
====================
4/CD
)/)
is/VBZ
on/IN
the/DT
increase/NN
for/IN
all/DT
models/NNS
./.
====================
The/DT
disease/NN
SNP/NN
17/CD
,/,
the/DT
power/NN
increases/VBZ
for/IN
all/DT
models/NNS
except/IN
dominant/JJ
model/NN
(/(
Fig/NN
./.
====================
5/CD
)/)
./.
====================
The/DT
SNP/NN
30/CD
(/(
Fig/NN
./.
====================
6/CD
)/)
is/VBZ
on/IN
the/DT
increase/NN
for/IN
all/DT
models/NNS
./.
====================
The/DT
disease/NN
SNP/NN
34/CD
has/VBZ
the/DT
increasing/VBG
pattern/NN
except/IN
recessive/JJ
model/NN
(/(
Fig/NN
./.
====================
7/CD
)/)
./.
====================
The/DT
SNP/NN
45/CD
(/(
Fig/NN
./.
====================
8/CD
)/)
is/VBZ
on/IN
the/DT
increase/NN
for/IN
all/DT
models/NNS
./.
====================
We/PRP
use/VBP
Chi-square/JJ
test/NN
for/IN
testing/NN
allelic/JJ
association/NN
and/CC
genotype/NN
analyses/NNS
./.
====================
We/PRP
do/VBP
not/RB
show/VB
all/DT
other/JJ
disease/NN
SNPs/NNS
in/IN
the/DT
paper/NN
but/CC
in/IN
general/JJ
,/,
statistical/JJ
power/JJR
for/IN
most/JJS
disease/NN
SNPs/NNS
is/VBZ
likely/JJ
to/TO
increase/VB
by/IN
increase/NN
in/IN
the/DT
ratio/NN
of/IN
control/JJ
to/TO
case/NN
./.
====================
In/IN
summary/NN
,/,
we/PRP
show/VBP
that/IN
given/VBN
other/JJ
factors/NNS
such/JJ
as/IN
prevalence/NN
,/,
magnitude/NN
of/IN
effect/NN
,/,
and/CC
required/VBD
level/NN
of/IN
statistical/JJ
significance/NN
α/IN
,/,
significant/JJ
increase/NN
in/IN
statistical/JJ
power/JJR
can/MD
be/VB
obtained/VBN
by/IN
increasing/VBG
the/DT
ratio/NN
of/IN
control/JJ
to/TO
case/NN
./.
====================
Henceforth/RB
,/,
investigators/NNS
conducting/VBG
such/JJ
a/DT
study/NN
where/WRB
cases/NNS
are/VBP
limited/JJ
might/MD
consider/VB
increase/VBP
in/IN
the/DT
ratio/NN
of/IN
control/JJ
to/TO
case/NN
./.
====================
Further/RB
investigation/NN
may/MD
be/VB
needed/VBN
for/IN
real/JJ
data/NNS
./.
====================
And/CC
other/JJ
factors/NNS
which/WDT
affect/VBP
the/DT
power/NN
need/VBD
to/TO
be/VB
considered/VBN
./.
====================
